Here we present available company earnings for 1Q11. Our estimates place overall market growth at 4% over 1Q10, as seen in Exhibit 1, which displays 1Q orthopaedic sales growth by product segment for select companies. Performance highlights follow. Highlights pertain to 1Q11 unless otherwise noted.
Exhibit 1: Orthopaedic Sales1 Increases by Product Segment: 1Q11 vs. 1Q10
Notes to Exhibit 1
1Orthopaedic products only; constant currency, pro forma growth
3For the quarter ended 2/28/11; trauma includes stimulators; spine includes stimulators and orthobiologics.
4For the quarter ended 4/29/11
6For the quarter ended 3/31/11
7Extremities: Extremities + Fixation combined; Endoscopy: Endoscopic + Communications, mostly orthopaedic; Spine: Neuro + Spine. Total growth excludes Patient Handling.
9Excludes Other (Aerospace)